Search

Displaying results 1821 - 1830 of 7604 in total
  1. Drug

    Human papillomavirus type 6 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10299
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 6 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.

    Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASIL SUSPENSION FOR INJECTION
  2. Drug

    NRP409

    go.drugbank.com/drugs/DB05235
    Experimental

    NRP409 is a triiodothyronine (T3) hormone, being investigated by New River Pharmaceuticals as a treatment for patients with primary hypothyroidism.

  3. Drug

    Fidaxomicin

    go.drugbank.com/drugs/DB08874
    ApprovedInvestigational

    [A190486] The minimum inhibitory concentration (MIC<sub>90</sub>) for fidaxomicin is four times less than that of [vancomycin], which was the primary drug of choice for _C. difficile_ infection before … [A190516] The FDA initially approved fidaxomicin in May 2011 for the treatment of _C. difficile_-associated diarrhea in adult patients over the age of 18.

  4. Drug

    Human papillomavirus type 11 L1 capsid protein antigen

    go.drugbank.com/drugs/DB10300
    ApprovedInvestigational

    It is an immunization for young men and women 9-26 years of age for the prevention of diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18. … Human papillomavirus type 11 L1 capsid protein antigen is contained in Gardasil, or a recombinant Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) vaccine for intramuscular injection.

    Mixtures: GARDASIL 9 SUSPENSION FOR INJECTION, GARDASIL SUSPENSION FOR INJECTION
  5. Drug

    Ziprasidone

    go.drugbank.com/drugs/DB00246
    ApprovedInvestigational

    [A190525] Luckily, several treatment options for psychotic disorders have been introduced to market since the realization of chlorpromazine's antipsychotic properties in 1952. … [A180748] Although ziprasidone is classified as an atypical antipsychotic, it appears to have a lower incidence of metabolic adverse effects compared to other medications in the same class.[A190525]

  6. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    feature allows them to be hypoimmunogenic and non-inducible for tumorigenesis. … Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue.

  7. Drug

    Ardeparin

    go.drugbank.com/drugs/DB00407
    ApprovedWithdrawn

    Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. … Normiflo was withdrawn from the US market in March 2000.

  8. Drug

    Avasopasem manganese

    go.drugbank.com/drugs/DB16354
    Investigational

    [L27246, L27256] This drug has potential application for radiation-induced esophagitis and oral mucositis, in addition to being currently tested against COVID-19. … Avasopasem manganese, also known as GC4419, is a highly-selective small molecule mimetic of superoxide dismutase (SOD) being investigated for the reduction of radiation-induced severe oral mucositis.

  9. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    [L46237] In April 2023, the US FDA declined to approve mirikizumab for the treatment of ulcerative colitis on the basis of manufacturing concerns. … [L46252] It was officially approved in the EU in May 2023[L48656] and Canada in July 2023[L48661], and was eventually approved in the US in October 2023[L48651] for the treatment of adult patients with

  10. Drug

    Medroxyprogesterone acetate

    go.drugbank.com/drugs/DB00603
    ApprovedInvestigational

    Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. … abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prevent pregnancy, manage pain in endometriosis, prevent pregnancy, and is also used in palliative care for

    Categories: Hormonal Contraceptives for Systemic Use, Contraceptive Agents, Male